ClinicalTrials.gg
Not yet recruitingNCT07647146Updated Jun 15, 2026

Corneal Epithelial Thickness Mapping by Anterior Segment Optical Coherence Tomography in Patients With Refractive Errors

An observational study in Myopia, Hyperopia and Astigmatism, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Sohag University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
360
Ages
18 Years to 99 Years
Sex
All
01

Study summary

This study evaluates corneal epithelial thickness using anterior segment optical coherence tomography (AS-OCT) in patients with refractive errors. It aims to assess the relationship between epithelial thickness patterns and different types of refractive errors.

Read the detailed description

Refractive errors are among the most common ocular conditions affecting visual acuity. Corneal epithelial thickness has been suggested to play a role in the optical properties of the eye and may vary among different refractive states. This observational study aims to evaluate corneal epithelial thickness mapping using anterior segment optical coherence tomography (AS-OCT) in patients with refractive errors. Patients will be assessed and categorized according to their refractive status, and epithelial thickness measurements will be obtained and analyzed. The study seeks to investigate potential correlations between epithelial thickness distribution and different types of refractive errors to enhance understanding of corneal biomechanics in refractive conditions.

02

Conditions studied

  • Myopia
  • Hyperopia
  • Astigmatism
  • Emmetropia

Keywords

  • Corneal epithelial thickness, AS-OCT, anterior segment optical coherence tomography, refractive errors, myopia, hyperopia, astigmatism, cornea
03

In context

Myopia

1,159 studies on the registry are indexed under Myopia; 225 are open to participants now.

This study's planned enrollment of 360 is above the median of 150 across 204 observational studies indexed under Myopia.

Browse Myopia studies →

Lead sponsor

Sohag University is the lead sponsor of 1,230 studies on the registry; 636 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adult participants (≥18 years) with refractive errors, including myopia, hyperopia, and astigmatism, as well as emmetropic subjects, recruited from the Ophthalmology Department and undergoing anterior segment optical coherence tomography (AS-OCT) examination.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years-
  • Patients diagnosed with myopia or hyperopia by refraction
  • Clear cornea with no evidence of corneal pathology
  • Ability to undergo reliable anterior segment imaging

Exclusion criteria

Exclusion Criteria:

  • Inability to fixate or follow instructions
  • Family history of keratoconus
  • Glaucoma,Cataract
  • Previous ocular surgery including refractive surgery
  • Keratoconus or suspected corneal ectasia
  • Corneal opacities or scars
  • Contact lens wear within the last two weeks
  • Ocular trauma
  • systemic disease affecting the cornea ( Such as diabetes)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
360 participants (estimated)
Patient registry
No

Groups and cohorts

  • All Participants

    All participants diagnosed with refractive errors (myopia, hyperopia, astigmatism) and emmetropia will be included in the study. All subjects will undergo anterior segment optical coherence tomography (AS-OCT) for corneal epithelial thickness mapping. Participants will then be analyzed according to their refractive status.

06

What researchers measure

Primary outcomes

  1. Measurement of corneal epithelial thickness using AS-OCT

    Corneal epithelial thickness will be measured using anterior segment optical coherence tomography (AS-OCT). Measurements will include central and regional epithelial thickness values in microns in patients with different refractive errors.

    Time frame: At baseline during a single study visit when participants undergo AS-OCT examination.

Secondary outcomes

  1. Comparison of epithelial thickness between myopic and hyperopic eyes

    Corneal epithelial thickness will be compared between myopic and hyperopic eyes using AS-OCT measurements.

    Time frame: At baseline (single visit)

  2. Comparison of epithelial thickness in eyes with and without astigmatism

    Corneal epithelial thickness will be evaluated and compared between eyes with astigmatism and those without astigmatism using AS-OCT.

    Time frame: At baseline (single visit)

  3. Corneal epithelial thickness asymmetry across corneal regions and inter-eye comparison

    Epithelial thickness will be assessed across different corneal regions and compared between both eyes to evaluate inter-eye asymmetry.

    Time frame: At baseline (single visit)

  4. Comparison of epithelial thickness in low and high refractive errors

    Corneal epithelial thickness profiles will be compared between low and high degrees of myopia and hyperopia using AS-OCT measurements.

    Time frame: At baseline (single visit)

07

Study locations

1 site
  • Sohag University Hospital
    Sohag, Sohag Governorate 82524, Egypt
    • Engy Mohamed Mostafa, Professor · ContactEngymostafa@yahoo.com · 01005643587
    • Amin Abu-Ali Hassan, Assistant Professor · Contact01015437008
    • Engy Mohamed Mostafa, Professor · Principal investigator
    • Amin Abu-Ali Hassan, Assistant Professor · Sub investigator
    • Yasmeen Gamal Abd-El latif, Lecturer · Sub investigator
    • Merna Romany Loza, MBBCh, Ophthalmology Resident · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07647146
Lead sponsor
Sohag University
Responsible party
Merna Romany Kamel (Sub-investigator(resident), Sohag University) — Principal investigator
First posted
Jun 15, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Jun 15, 2026

Study contacts

Merna romany loza, MBBCh, Ophthalmology Resident
Contact
mernaromany54@yahoo.com
01275800331
Engy Mohamed Mostafa, Professor
Contact
Engymostafa@yahoo.com
01005643587
Engy Mohamed Mostafa, Professor
principal investigator · Department of Ophthalmology, Faculty of Medicine, Sohag University
Amin Abu-Ali Hassan, Assistant Professor
study director · Department of Ophthalmology, Faculty of Medicine, Sohag University
Yasmeen Gamal Abd-El latif, Lecturer
study director · Department of Ophthalmology, Faculty of Medicine, Sohag University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion